Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$0.26 CAD
Change Today -0.03 / -10.53%
Volume 43.6K
GEN On Other Exchanges
As of 1:27 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

genenews ltd (GEN) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/4/14 - C$1.94
52 Week Low
08/24/15 - C$0.24
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for GENENEWS LTD (GEN)

Related News

No related news articles were found.

genenews ltd (GEN) Related Businessweek News

No Related Businessweek News Found

genenews ltd (GEN) Details

GeneNews Limited, a molecular diagnostics company, focuses on developing and commercializing proprietary molecular diagnostic tests for early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology, the Sentinel Principle, identifies novel biomarkers from whole blood. The company’s lead product is ColonSentry, a blood-based test for assessing an individual’s current risk of for having colorectal cancer. GeneNews Limited was founded in 1998 and is headquartered in Markham, Canada.

4 Employees
Last Reported Date: 03/31/15
Founded in 1998

genenews ltd (GEN) Top Compensated Officers

Executive Chairman, Member of Compensation & ...
Total Annual Compensation: --
Chief Financial Officer, Treasurer, Director ...
Total Annual Compensation: C$176.7K
Compensation as of Fiscal Year 2014.

genenews ltd (GEN) Key Developments

GeneNews Limited Reports Financial Results for the Second Quarter Ended June 30, 2015

GeneNews Limited reported financial results for the second quarter ended June 30, 2015. For the three months ended June 30, 2015, total revenues were approximately CAD 730,000 as compared to CAD 440,000 in the same period in 2014. The net loss for the second quarter of 2015 was approximately CAD 1.6 million, or CAD 0.03 loss per common share, as compared to a net loss of approximately CAD 2.7 million, or CAD 0.06 loss per common share, for second quarter of 2014.

GeneNews' Innovative Diagnostic Laboratory J-V Appoints Dr. Joel V. Brill as Chief Medical Officer

GeneNews Limited announced the appointment of Dr; Joel V. Brill, MD as the Chief Medical Officer of its Innovative Diagnostic Laboratory, LLP joint-venture. In his new role, Dr. Brill will assume leadership responsibility for the medical aspects of IDL's laboratory, and act as the company's medical lead with physicians, patients and insurance providers. Dr. Brill will serve on IDL's executive committee as its medical representative, providing strategic counsel on current and new products, the identification of new technologies, and reimbursement issues. Dr. Brill is an executive clinician with 30 years of experience providing strategic leadership and medical oversight to data-driven health organizations, skilled in strategy, development and implementation of innovative health programs, products and payment systems, with extensive experience in clinical practice and research.

GeneNews Seeks Acquisitions

"While GeneNews will continue to contribute to its growth through internal pipeline development, third-party licenses and potential acquisitions of novel, proprietary tests, increasing our ownership interest in IDL will provide us with greater management and cost control, more direct input and a higher share of the joint-venture's economics", said Howard-Tripp, Executive Chairman of GeneNews Limited (TSX:GEN).


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GEN:CN C$0.26 CAD -0.03

GEN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GEN.
View Industry Companies

Industry Analysis


Industry Average

Valuation GEN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.8x
Price/Book 8.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENENEWS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at